Navigation Links
Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
Date:9/10/2009

tatements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of Sept. 9, 2009 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnership
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
2. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
3. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
4. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
7. Medarex to Receive Milestone Payment from Amgen
8. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
9. Bionovo Announces Second Quarter 2009 Highlights and Financial Results
10. Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
11. July 2009 Mayo Clinic Womens HealthSource Highlights Food Storage Safety, Energy Therapies and Vitamins and Minerals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014  Alimera Sciences, Inc. (NASDAQ: ALIM ... research, development and commercialization of prescription ophthalmic pharmaceuticals, announced ... from Hercules Technology Growth Capital, Inc. (NYSE: ... final advance under the Loan and Security Agreement that ... , Alimera Sciences Limited, entered into with Hercules in ...
(Date:9/30/2014)... 30, 2014 A study using a relatively ... new look at the composition of carotid artery disease ... and treat the disease, a leading cause of stroke. ... Lexington between September 2010 and May 2012, was featured ... of the American College of Cardiology (JACC) Cardiovascular Interventions. ...
(Date:9/30/2014)... , Sept. 30, 2014 Valeant Pharmaceuticals International, ... today announced that the company,s Bridgewater, New ... the U.S. Food and Drug Administration (FDA) relating to ... with regards to Sculptra Aesthetic injectable, which was divested ... to the management of Valeant,s contract manufacturers (rather than ...
Breaking Medicine Technology:Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
(Date:9/30/2014)... Hospice & Palliative Care of ... gala, honoring three outstanding individuals for their commitment ... provide extraordinary and dignified comfort, care and compassion ... life-limiting illness. , The event was held at ... recognized William (Bill) J. McGuinness, Director of Tiffany ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Dr. Karl ... knee pain program of care that is dramatically ... , His clinic—Johnson Chiropractic Neurology & Nutrition—applies a proprietary, ... knee. It also addresses sources of inflammation, neurology of ... the “neurokinetic chain” from the brain to the spine, ...
(Date:9/30/2014)... WASHINGTON (Sept. 30, 2014) Levothyroxine is considered the ... and a new review of therapies for the condition ... not altered that assessment, say a team of investigators.,1Their ... journal Thyroid , finds insufficient consistent data exist ... whether generic, or sold under various trade names, such ...
(Date:9/30/2014)... IL (PRWEB) September 30, 2014 Healthcare ... at the National Association of Health Advocacy Consultants (#NAHAC) ... Healthcare Advocacy” (#NAHAC14) to be held October 30th - ... its debut at NAHAC14: Standards and Best Practices for ... grows into a profession, advocates have needed a set ...
(Date:9/30/2014)... September 30, 2014 Market Research ... is a professional and in-depth market survey on ... reviews the basic information of Cialis including its ... explores global and China’s top manufacturers of Cialis ... market share etc. , The report further analyzes ...
Breaking Medicine News(10 mins):Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 3Health News:New guidelines for treatment of hypothyroidism endorse current therapy 2Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4
... , TUESDAY, March 1 (HealthDay News) -- A ... hospitals for sepsis -- a potentially life-threatening bacterial infection in ... those treated at other hospitals. Researchers analyzed data from ... sepsis between June 2004 and June 2006. In total, there ...
... over time been able to show that medicine designed ... serious diseases such as cancer. However, now research also ... part in the drug delivery process. "Researchers ... of viruses. The nanoparticles are effective for drug delivery ...
... ATLANTA March 1, 2011 A new report from ... the 141,000 cases and 49,000 deaths from colorectal cancer ... prevented by increasing the use of established screening tests ... The report, Colorectal Cancer Facts & Figures 2011-2013, released ...
... Invasive plant species have long had a reputation as being ... Stan Harpole, assistant professor of ecology, evolution and organismal biology ... of more than 70 researchers working at 65 sites worldwide ... it is true that problematic invasive species often spread widely ...
... Los Angeles, CA (February 28, 2011) Eating more tomatoes ... the risk of conditions such as cancer, osteoporosis and ... American Journal of Lifestyle Medicine , (published by SAGE). ... tomatoes and tomato products than any others. Researchers Britt ...
... , TUESDAY, March 1 (HealthDay News) -- For ... to relieve symptoms and result in major improvements in ... Up to 20 percent of women in their childbearing ... Not all fibroids cause symptoms, but some patients experience ...
Cached Medicine News:Health News:Hospital Spending Doesn't Affect Sepsis Survival Rates 2Health News:Research provides new findings on drug delivery with nanoparticles 2Health News:New report says large proportion of colorectal cancer deaths could be prevented 2Health News:Global ISU study: Invasive species widespread, but not more than at home range 2Health News:Health benefits of eating tomatoes emerge 2Health News:Uterine Fibroid Treatments Seem to Boost Quality of Life 2
... Focus from Thermo Labsystems was designed specifically ... Advanced features such as the new fast ... on microvolumes help to define this as ... The new interchangeable handle plate offers a ...
... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... "pipette/tip" system ensures utmost accuracy and precision. ...
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
Medicine Products: